News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Daiichi Sankyo, Inc. (4568.t) And Eli Lilly and Company (LLY): Heart Patients In England And Wales Offered More Choice Of Therapies As National Institute for Clinical Excellence (NICE) Extends Recommendations For Prasugrel


7/23/2014 11:01:12 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

GERRARDS CROSS, England--(BUSINESS WIRE)--Revised guidance from the National Institute for Health and Care Excellence (NICE), recommends once-daily, oral antiplatelet prasugrel (EfientĀ®), in combination with aspirin, as a cost-effective option when compared to generic clopidogrel, for a wider group of acute coronary syndrome (ACS) patients having primary or delayed percutaneous coronary intervention (PCI).1

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES